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both the psoriasis or DM gene expres-
sion values using a 100-gene moving
window (Figure 2e).
Interestingly, the gene expression
pattern was very similar among our
patient, DM, and psoriasis over clusters
3, 5, 7, which had enrichment of
genes involved in lipid metabolism,
type I IFN pathway activation, and
T-cell function (Figure 2f). However,
for clusters 1, 2, 4, and 6, our patient
displayed gene expression patterns
more consistent with DM than psor-
iasis. These clusters were enriched
with genes involved in lipid metabo-
lism, extracellular matrix synthesis,
mucin synthesis, complement cascade,
and angiogenesis. There was a cluster
of genes involved in proliferation and
cell cycle differentiation (cluster 8)
where our patient showed molecular
similarity to psoriasis. This observation
is consistent with the increased epi-
dermal thickness (and proliferation)
seen on histology.
Four years after presentation, our
patient developed proximal muscle
weakness and dysphagia with corre-
sponding elevation in creatine kinase
and aldolase. Her electromyography
showed evidence of chronic inflamma-
tory proximal myopathy with active
dennervation features. Her skin rash
remained similar to initial presentation.
Thus, she fulfilled four out of five
criteria of Bohan and Peter (1975)
(rash, elevated muscle enzymes,
proximal weakness, and abnormal
electromyography), confirming a diagnosis
of DM. This case demonstrates the
diverse ways in which DM can present,
compares the molecular profile between
psoriasis and DM, and highlights the
utility of molecular profiling to aid in
diagnosis where histopathologic criteria
may be inconclusive.
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TO THE EDITOR
Erythema exsudativum multiforme majus
(EEMM) is a rare condition affecting both
skin and mucous membranes. It is
assumed that humoral immune reponses
may contribute to the pathogenesis of the
disease, and the presence of autoantibo-
dies was described in 7 of 10 EEMM
patients (Foedinger et al., 1995, 1996).
These autoantibodies were associated
with desmosomal staining by direct
immunofluorescence microscopy of skin
and by indirect immunofluorescenceAccepted article preview online 6 June 2013; published online 11 July 2013
Abbreviation: EEMM, erythema exsudativum multiforme majus
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tests using monkey esophagus as a
substrate, and they produced 210/
250 kDa bands by immunoblotting
of epidermal extracts, and immuno-
precipitated proteins of apparently
210/250 kDa from lysates of human
keratinocytes. Desmoplakin I/II were
proposed as autoantigens owing to
similar reaction pattern of a mono-
clonal anti-desmoplakin antibody. In a
follow-up study, IgG from an EEMM
patient, purified via synthetic desmo-
plakin1735-176, produced skin lesions
when injected into newborn mice, indi-
cating a specific pathogenetic relevance
(Foedinger et al., 1998). This latter inter-
pretation has been challenged because of
the atypical acantholysis seen in the
mice, (Johnson et al., 1999) as well as
in index patients. Moreover, autoanti-
bodies against desmoplakin I/II, as well
as against the similarly structured peri-
plakin, (Park et al., 2006) have been
described in other skin diseases such
that anti-plakin autoantibodies might
appear as epiphenomena of exten-
sive epidermal damage (Cozzani et al.,
2011).
In the present study, we analyzed sera
from 54 patients with early EEMM (sam-
ples were obtained median 9 days after
initial symptoms, range 3–14 days) with
a multitude of different serological test
systems, including assays for anti-envo-
plakin and anti-periplakin (Probst et al.,
2009). The sera were provided by the
RegiSCAR study group (Genin et al.,
2011) and were from 21 female, as
well as from 33 male, patients (median
age 14.5 years, range 5–72 years). All
cases were reviewed by independent
dermatologists blinded to potential
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Figure 1. Analysis of sera for autoantibodies against envoplakin and periplakin by immunoblotting and indirect immunofluorescence. (a) Immunoblotting of total
lysates of HaCaT cells separated by SDS–PAGE. (b) Immunoblotting of recombinant envoplakin and periplakin expressed in HEK293. Cell-free supernatants of
3 105 HEK293 cells expressing envoplakin or periplakin were mixed and applied to SDS–PAGE. Native (a) and recombinant (b) envoplakin (210 kDa) and
periplakin (195 kDa) were stained with specific antibodies and were also recognized by autoantibodies in a PNP reference serum. Arrow heads: migration position
of 200-kDa molecular-weight marker. (c) Immunofluorescence staining of HEK293 expressing recombinant envoplakin (top), periplakin (middle), or nontransfected
cells (bottom). For visualization of antibody binding, Cy3-labeled appropriate conjugates were used. Bar ¼ 20mm. DPL, murine mAb to desmoplakin I/II;
EMM, representative sera from patients with erythema exsudativum multiforme majus; EPL, anti-envoplakin rabbit serum; His, murine monoclonal against
hexa-histidine; NHS, reference serum from a healthy blood donor; PNP, reference serum from a patient with paraneoplastic pemphigus; PPL, anti-periplakin rabbit
serum.
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causes of the disease (Bastuji-Garin
et al., 1993; Mockenhaupt et al., 1999;
Auquier-Dunant et al., 2002) and
validated as ‘‘probable’’ or ‘‘definite’’
EEMM.
Purified proteins, HEK293 extracts, or
HaCaT extracts were analyzed both by
immunoblotting (Probst et al., 2009)
or by protein G–based immuno-
precipitation–immunoblot (IP–IB). ELISA
for the detection of antibodies against
bacterially expressed fragments of envo-
plakin and periplakin was conducted
as described (Probst et al., 2009). For
indirect immunofluorescence test, slides
with a mosaic of native substrates were
used, including HEp-2 cells, human
neutrophils, thrombocytes, spermatozoa,
primate thyroid, parathyroid, adrenal
gland, stomach, pancreas, liver, heart,
lung, placenta, musculus iliopsoas,
parotis, nervus suralis, testis, monkey
esophagus, kidney, cerebellum, cere-
brum, hypophysis, hypothalamus, spinal
cord, intestine, ovary, rat kidney, liver,
and crithidia (Euroimmun, Germany). In
addition, slides were used containing
human skin, primate epiglottis, primate
vas deferens, and rat bladder, as well
as fixed HEK293 cells expressing recom-
binant desmoglein 1 (Schmidt et al.,
2010), desmoglein 3 (Schmidt et al.,
2010), full-length periplakin or envo-
plakin, collagen VII-NC1 (Komorowski
et al., 2013), and BP230 (Blo¨cker et al.,
2012), and bacterially expressed
BP180-NC16 (extracellular part of the
16th noncollagenous domain of BP180;
4 ) (Sitaru et al., 2007). Desmoplakin
I/II, envoplakin, and periplakin stain-
ing patterns in native substrates were
established using monospecific anti-
bodies as described (Probst et al., 2009).
The 54 EEMM sera did not produce
any specific bands by immunoblotting
of HaCaT extract, whereas the mAb to
desmoplakin I/II showed the expected
pattern (Figure 1a). The same negative
results were obtained when the
extract was used in IP–IB or extracts of
HEK293 expressing full-length envopla-
kin and periplakin (Figure 1b), respec-
tively, or their bacterially produced
fragments were used for immunoblot-
ting. By ELISA using either of 11 frag-
ments of envoplakin and periplakin, no
readings above their individual cutoffs
were observed.
Indirect immunofluorescence test
using HEK293 expressing envoplakin
Figure 2. Immunofluorescence staining of primate tissues. Immunofluorescence staining of primate esophagus (left), rat bladder (next to left), primate epiglottis
(next to right), and primate vas deferens (right) by reference antibodies to desmoplakin I/II (top), envoplakin (middle), and periplakin (bottom). A reference serum
from a patient with paraneoplastic pemphigus, showing reactivity with envoplakin and periplakin by ELISA and immunoblotting, produced similar staining
patterns, but none of the sera from EEMM patients showed these patterns (not shown). For the visualization of antibody binding, appropriate Cy3-labeled
conjugates were used. Bar ¼ 50mm.
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and periplakin, respectively (Figure 1c),
or mammalian tissues as substrates
was employed as a means of using
nondenatured proteins. Monospecific
anti-envoplakin, anti-periplakin, and
anti-desmoplakin antibodies stained
desmosomal structures in a variety of
tissues (Figure 2). The reference para-
neoplastic pemphigus serum produced
comparable stainings, in contrast to
sera from healthy blood donors. Inter-
estingly, none of the 54 EEMM sera
produced a plakin staining pattern.
Moreover, none of the EEMM sera
reacted with any of the other recom-
binant autoimmune skin disease–
related indirect immunofluorescence
test substrates, and they did not gen-
erate characteristic desmosomal or
basement membrane staining patterns
on monkey esophagus. The analysis of
staining patterns on the multitude of
native substrates did not reveal any
common reactivity. Eleven sera con-
tained low titers of anti-nuclear or
anti-thyroid antibodies without speci-
fic disease associations.
The work by Foedinger et al. indi-
cated the presence of autoantibodies
against desmoplakin I/II in 7 of 10
EEMM sera. Epitopes targeted by these
sera appeared to be independent on a
correct folding. Therefore, it is unlikely
that our negative results are due to the
use of denatured antigen. Moreover, we
did not find reactivity of EEMM sera
against any of the envoplakin or peri-
plakin variants. We did also not find
reactivity with other desmosomal pro-
teins or any other specific staining
pattern in EEMM patients. In fact, our
results do not support the hypothesis
that a major B-cell autoimmune
response is mounted in the early stages
of EEMM or that this disease is mediated
by autoantibodies.
One reason for the different out-
come of our study compared with the
initial work (Foedinger et al., 1995,
1996) might be the tight window
between diagnosis of the disease and
serum sampling in our cohort. This
may have reduced the detection of
epiphenoma following the preceding
tissue destruction due to an extended
inflammatory response (Cozzani et al.,
2011). Another reason may be
associated with the use of different
criteria for diagnosing EEMM in the
previous studies. In those studies, a
salient finding had been the presence
of acantholysis in skin biopsies, which is
actually an atypical feature in early
EEMM (Johnson et al., 1999). Possibly,
patients included in the studies by
Foedinger et al. suffered from an atypi-
cal variant of pemphigus or paraneo-
plastic pemphigus without associated
malignancy.
In conclusion, our results contradict
the notion that EEMM is an autoimmune
disease that is induced by a humoral
anti-self response.
This study adhered to the Declaration
of Helsinki protocols. Study participants
gave written, informed consent, and
institutional approval was obtained in
each country separately.
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